Achieve Life Sciences Stock (NASDAQ:ACHV)

Forecast Ownership Financials Chart Transcripts

Previous Close

$7.84

52W Range

$2.62 - $8.64

50D Avg

$6.99

200D Avg

$5.18

Market Cap

$774.05M

Avg Vol (3M)

$1.87M

Beta

2.25

Div Yield

ACHV Company Profile

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 12, 1995

Website

ACHV Performance

ACHV Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-54.88M	$-39.07M	$-27.25M
Net Income	$-54.65M	$-39.83M	$-29.82M
EBITDA	$-54.65M	$-37.42M	$-26.73M
Basic EPS	$-1.25	$-1.24	$-1.50
Diluted EPS	$-1.25	$-1.24	$-1.50

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 12, 26 | 8:30 AM

Q4 25Mar 24, 26 | 8:30 AM

Q3 25Nov 06, 25 | 8:30 AM

Peer Comparison

Ticker	Company
TRDA	Entrada Therapeutics, Inc.
HUMA	Humacyte, Inc.
IMRX	Immuneering Corporation
AVIR	Atea Pharmaceuticals, Inc.
ALLO	Allogene Therapeutics, Inc.
SGMT	Sagimet Biosciences Inc.
CAPR	Capricor Therapeutics, Inc.
VNDA	Vanda Pharmaceuticals Inc.
ARCT	Arcturus Therapeutics Holdings Inc.
VYGR	Voyager Therapeutics, Inc.